Moleculin Biotech Reports Second Quarter 2026 Financial Results And Highlights Continued Advancement Of Pivotal Miracle Trial
MBRX•Reuters brief on second-quarter results and trial update
Aug. 14 (Reuters) - Moleculin Biotech Inc. MBRX.O:
- Moleculin Biotech reports second quarter 2026 financial results and highlights continued advancement of pivotal Miracle trial
Source text: ID:nGNXdkBRf
Further company coverage: MBRX.O
